FDA Places Hold on Iovance’s Lung Cancer Treatment Trial
Lung cancer is one of the most deadly diseases all around the world. Various companies are during clinical trials to offer better and effective treatment options for those suffering from lung cancer. The US Food and Drug Administration has placed a clinical hold on Iovance Biotherapeutics’ IOV-LUN 202 trial of LN-145 tumor infiltrating lymphocyte therapy
